Core B: Single Cell Protein and RNA Sequencing Core
Core B: Single Cell Protein and RNA Sequencing Core
批准号:
10334092
负责人:
Klaus F. Ley
金额:
$5.35万
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-08-01 至 2022-06-02
关键词:
ATAC-seqAntibodiesAtherosclerosisB-LymphocytesB-cell receptor repertoire sequencingBindingBioinformaticsBiostatistics CoreCardiovascular systemCell CommunicationCellsClinicalCytometryDNA Sequencing FacilityDataEpidemiologistExcisionExperimental DesignsGenomicsGuidelinesHumanImmuneLeukocytesLightManuscriptsMeta-AnalysisMusOligonucleotidesPeptide Sequence DeterminationPeripheral Blood Mononuclear CellPhenotypePostdoctoral FellowProgress ReportsPublishingQuality ControlResearchRunningSamplingServicesShippingSignal TransductionT cell receptor repertoire sequencingT-LymphocyteTissuesVisualizationWorkbasecohortcomputerized data processingdata qualitydesignexperiencehuman dataimprovedmacrophagemonocytesingle cell proteinssingle-cell RNA sequencingtranscriptome sequencing
中文摘要
核心B摘要
核心B为PPG中的所有4个项目提供服务,以满足所有RNA测序需求,包括散装和单细胞RNA-
测序(scRNA-Seq)、寡核苷酸标记抗体蛋白质测序(Ab-Seq)、T细胞和B细胞
受体测序(TCR-Seq和BCR-Seq)和ATAC-Seq。核心B负责所有质量控制
沿着工作流程。核心B工作人员由湿实验室工作人员和生物信息学家组成。他们与博士后互动,
人类临床心血管和生物统计核心(临床)的技术人员、流行病学家和PI
核心C)和四个项目中的每一个。为小鼠(巨噬细胞、分类T细胞)建立了工作流
细胞)和人(PBMC)细胞。标签和抗体是完全有效的,包括阈值,这
通过消除来自未结合抗体和非特异性抗体结合的信号来提高数据质量。这个
此核心的先前版本(2016 Hedrick PPG中的核心E)是世界上第一个使用scRNA-
SEQ在动脉粥样硬化研究中的应用。我们制定并发布了工作流程和质量控制指南,
ScRNA-Seq、批次效应、二倍体和死细胞去除。核心B提供湿实验室和生物信息学服务
加上与所有4个项目和核心C的良好接口,对于Ab-Seq,我们验证了192个寡核苷酸-
标记人抗体面板(Biolegend),运行在10倍基因组5‘上,将用于大多数
拟议的人体研究。对于小鼠,我们使用带有10x基因组的Biolegend 138小鼠抗体小组
5‘。利用这个平台,我们已经成功地组装了数以万计的TCRα和β链对(SCTCR-
SEQ)和BCR重链和轻链对(scBCR-Seq)。所有4个项目都使用核心B。具体目标是:(1)
为小鼠提供最优质的scRNA-Seq、Scab-Seq、scATAC-Seq、scTCR-Seq和ScBCR-Seq
和人体样本,包括全面记录和严格的质量控制,设计和优化
关于所有生物信息学问题的抗体小组和建议。(2)提供最高质量的大宗RNA-Seq和
用于老鼠和人类样本的ATAC-Seq,包括全面记录和严格的质量控制和
支持实验设计和规划。(3)有效、无缝地与博士后对接,
来自临床核心C和四个项目每个项目的技术人员、流行病学家和PI,包括
样品的运送、接收、解冻、数据处理、可视化和交付。为了提供这些服务,我们
已经建立了一支由湿实验室技术人员、生物信息学家和计算生物学家组成的团队。与所有
项目和核心C已经建立,并运行良好。
英文摘要
Core B Summary
Core B serves all 4 projects in this PPG for all RNA sequencing needs, including bulk and single cell RNA-
sequencing (scRNA-Seq), protein sequencing by oligonucleotide-tagged antibodies (Ab-Seq), T- and B-cell
receptor sequencing (TCR-Seq and BCR-Seq) and ATAC-Seq. Core B is responsible for all quality controls
along the workflow. Core B staff consists of wet lab staff and bioinformaticians. They interact with postdocs,
technicians, epidemiologists and PIs from the Human Clinical Cardiovascular and Biostatistics Core (Clinical
Core C) and from each of the four projects. Workflows are established for mouse (macrophages, sorted T
cells) and human (PBMC) cells. Hashtags and antibodies are fully validated, including thresholding, which
improves data quality by eliminating signal from unbound antibody and non-specific antibody binding. The
previous version of this core (core E in the 2016 Hedrick PPG) was the first group world-wide to use scRNA-
Seq in atherosclerosis research. We established and published guidelines for workflows and quality controls in
scRNA-Seq, batch effect, doublet and dead cell removal. Core B provides wet lab and bioinformatics service
plus well-developed interfaces with all 4 projects and core C. For Ab-Seq, we validated a 192 oligonucleotide-
tagged human antibody panel (Biolegend), run on 10x Genomics 5’, which will be used for Ab-Seq in most of
the proposed human studies. For mice, we use the Biolegend 138 mouse antibody panel with 10x Genomics
5’. Using this platform, we have successfully assembled tens of thousands of TCRα and β chain pairs (scTCR-
Seq) and BCR heavy and light chain pairs (scBCR-Seq). All 4 projects use core B. The specific aims are: (1)
To provide the highest quality scRNA-Seq, scAb-Seq, scATAC-Seq, scTCR-Seq and scBCR-Seq for mouse
and human samples, including fully documented and rigorous quality controls, designing and optimizing
antibody panels and advice on all bioinformatics issues. (2) To provide the highest quality bulk RNA-Seq and
ATAC-Seq for mouse and human samples, including fully documented and rigorous quality controls and
support for experimental design and planning. (3) To effectively and seamlessly interface with postdocs,
technicians, epidemiologists and PIs from the Clinical Core C and from each of the four projects, including
sample shipping, receiving, thawing, data processing, visualization and delivery. To provide these services, we
have built a team of wet lab technicians, bioinformaticians and computational biologists. Interfaces with all
projects and core C are established and working well.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Mechanism of kindlin-3-dependent integrin activation
-
批准号:10676897
-
项目类别:
-
资助金额:$54.92万
-
财政年份:2020
-
负责人:Klaus F. Ley
-
依托单位:
Mechanism of kindlin-3-dependent integrin activation
-
批准号:10229369
-
项目类别:
-
资助金额:$54.93万
-
财政年份:2020
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:10369710
-
项目类别:
-
资助金额:$58.9万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:10112954
-
项目类别:
-
资助金额:$90.72万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:9895858
-
项目类别:
-
资助金额:$90.7万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:10623034
-
项目类别:
-
资助金额:$31.83万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Vascular macrophages and T cells in atherosclerosis
-
批准号:10565907
-
项目类别:
-
资助金额:$76.97万
-
财政年份:2019
-
负责人:Klaus F. Ley
-
依托单位:
Core E: Cell sorting, CyTOF and RNA-Seq
-
批准号:10188604
-
项目类别:
-
资助金额:$54.45万
-
财政年份:2017
-
负责人:Klaus F. Ley
-
依托单位:
Super-resolution confocal microscope
-
批准号:9274885
-
项目类别:
-
资助金额:$56.63万
-
财政年份:2017
-
负责人:Klaus F. Ley
-
依托单位:
ApoB-specific CD4 T cells in mouse and human atherosclerosis
-
批准号:10188608
-
项目类别:
-
资助金额:$38.98万
-
财政年份:2017
-
负责人:Klaus F. Ley
-
依托单位:
Project 4: APOB-specific CD4 and CD8 T cells exacerbate atherosclerosis
-
批准号:10334097
-
项目类别:
-
资助金额:$4.3万
-
财政年份:2017
-
负责人:Klaus F. Ley
-
依托单位:
Vaccination with MHC-II restricted ApoB100 peptides to prevent atherosclerosis
-
批准号:8819012
-
项目类别:
-
资助金额:$45.55万
-
财政年份:2014
-
负责人:Klaus F. Ley
-
依托单位:
Vaccination with MHC-II restricted ApoB100 peptides to prevent atherosclerosis
-
批准号:8966694
-
项目类别:
-
资助金额:$43.63万
-
财政年份:2014
-
负责人:Klaus F. Ley
-
依托单位:
VASCULATA 2013: Vascular Immunology
-
批准号:8597858
-
项目类别:
-
资助金额:$1.25万
-
财政年份:2013
-
负责人:Klaus F. Ley
-
依托单位:
Myeloid cell interactions with T cells in atherosclerosis
-
批准号:8675936
-
项目类别:
-
资助金额:$42.48万
-
财政年份:2012
-
负责人:Klaus F. Ley
-
依托单位:
Myeloid cell interactions in atherosclerosis
-
批准号:9311933
-
项目类别:
-
资助金额:$45.0万
-
财政年份:2012
-
负责人:Klaus F. Ley
-
依托单位:
Myeloid cell interactions with T cells in atherosclerosis
-
批准号:8346057
-
项目类别:
-
资助金额:$56.61万
-
财政年份:2012
-
负责人:Klaus F. Ley
-
依托单位:
Myeloid cell interactions with T cells in atherosclerosis
-
批准号:8499418
-
项目类别:
-
资助金额:$43.3万
-
财政年份:2012
-
负责人:Klaus F. Ley
-
依托单位:
Myeloid cell interactions with T cells in atherosclerosis
-
批准号:9065736
-
项目类别:
-
资助金额:$43.35万
-
财政年份:2012
-
负责人:Klaus F. Ley
-
依托单位:
Cell Phenotyping Core
-
批准号:8703257
-
项目类别:
-
资助金额:$10.93万
-
财政年份:2008
-
负责人:Klaus F. Ley
-
依托单位:
海外基金